Nine More States Offer Medicaid Coverage for Breast and Cervical Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

WASHINGTON-Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.

WASHINGTON—Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000. 

Alabama, Georgia, Iowa, Mississippi, Missouri, North Dakota, South Carolina, Virginia, and Washington join 19 previously approved states.

Articles in this issue
High-Dose IL-2 Is Standard in Advanced Renal Cell Cancer
RIT Safe, Effective in Elderly and Poor-Prognosis Patients
FDA Approves Xeloda/Taxotere Combination for Advanced Breast Cancer
ODAC Recommends Approval of Radiolabeled Zevalin
Proteomics Moves From the Laboratory to Clinical Research
Radiotherapy Not Needed in Older Lumpectomy Patients With Early Cancer
Raltitrexed + Oxaliplatin for Advanced Colorectal Cancer
Mental Fatigue Worries Chemotherapy Patients
Patients Urged to Work With Professionals Against Fatigue
NCI Director Resigns to Head New Scientific Institute
Combined PET/CT Aids in Head and Neck Cancer Management
MRI Method Predicts Early Response
New Cellular Target Shows Promise in Cancer Treatment
ACR Protests Proposed Diagnostic Mammography Reimbursement Rates
High-Volume Hospitals Better for Some Cancer Surgeries
Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Related Content
Additionally, histologic subtype had a significant prognostic influence on PFS, as adenocarcinoma had doubled the risk of recurrence compared with squamous carcinoma, which had an equivalent risk of recurrence compared with adenosquamous carcinoma.

Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer

Tim Cortese
October 22nd 2025
Article

Patients with full-thickness or outer full-thickness stromal invasion following surgery had improved PFS when treated with SIB radiotherapy.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer

Kyle Doherty
October 20th 2025
Article

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.

Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer

Ashling Wahner
October 19th 2025
Article

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer

Roman Fabbricatore
October 19th 2025
Article

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.